Glycoprotein nonmetastatic melanoma protein B (GNMPB) as a novel biomarker for cerebral adrenoleukodystrophy.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 05 2022
14 05 2022
Historique:
received:
16
12
2021
accepted:
19
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
20
5
2022
Statut:
epublish
Résumé
Adrenoleukodystrophy (ALD) is an X-linked peroxisomal disease caused by a mutation in the ABCD1 gene, producing mutations in the very long chain fatty acid transporter, ALD protein. Cerebral ALD (cALD) is a severe phenotype of ALD with neuroinflammation and neurodegeneration. Elevated levels of Glycoprotein Nonmetastatic Melanoma Protein B (GNMPB) have been recently documented in neurodegenerative diseases such as Alzheimer's disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis. Our objective was to measure the levels cerebral spinal fluid (CSF) GNMPB in cALD patients to determine if GNMPB could be a potential biomarker in tracking cALD disease progression. CSF GNMPB levels were significantly higher in cALD patients versus controls (2407 ± 1672 pg/mL vs. 639.5 ± 404 pg/mL, p = 0.0009). We found a positive correlation between CSF GNMPB and MRI disease severity score levels (R
Identifiants
pubmed: 35568699
doi: 10.1038/s41598-022-11552-7
pii: 10.1038/s41598-022-11552-7
pmc: PMC9107455
doi:
Substances chimiques
Biomarkers
0
GPNMB protein, human
0
IgA receptor
0
Membrane Glycoproteins
0
Receptors, Fc
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7985Informations de copyright
© 2022. The Author(s).
Références
Antioxidants (Basel). 2021 Jun 24;10(7):
pubmed: 34202494
Neurology. 2020 Jun 16;94(24):e2499-e2507
pubmed: 32482842
J Neurosci Res. 2017 Aug;95(8):1647-1665
pubmed: 27935101
Int J Dev Neurosci. 2020 Feb;80(1):52-72
pubmed: 31909500
Kidney Int. 2011 May;79(10):1138-48
pubmed: 21389974
Brain Pathol. 2010 Jul;20(4):831-7
pubmed: 20626744
Am J Med Genet A. 2019 Jul;179(7):1205-1213
pubmed: 31074578
Eur J Paediatr Neurol. 2017 Jul;21(4):600-609
pubmed: 28274546
Blood. 2011 Aug 18;118(7):1971-8
pubmed: 21586746
PLoS One. 2012;7(11):e50430
pubmed: 23185624
Blood. 2004 Aug 1;104(3):881-8
pubmed: 15073029
J Neuroinflammation. 2011 Oct 20;8:144
pubmed: 22014002
PLoS One. 2012;7(2):e32218
pubmed: 22359672
Neurosci Res. 2021 Nov;172:73-79
pubmed: 34111442
Alzheimers Res Ther. 2021 May 4;13(1):94
pubmed: 33947460
AJNR Am J Neuroradiol. 2016 Feb;37(2):367-72
pubmed: 26427835
Int J Mol Sci. 2018 Dec 24;20(1):
pubmed: 30586924
Orphanet J Rare Dis. 2012 Aug 13;7:51
pubmed: 22889154
Arch Neurol. 2005 Jul;62(7):1073-80
pubmed: 16009761
J Neuroimmunol. 2008 Jun 15;197(1):70-3
pubmed: 18485490
Front Immunol. 2017 Dec 21;8:1810
pubmed: 29312322
Int J Cancer. 1995 Jan 3;60(1):73-81
pubmed: 7814155
Oncotarget. 2016 Mar 22;7(12):13932-44
pubmed: 26883195
J Cell Biochem. 2001;84(1):12-26
pubmed: 11746512
PLoS One. 2015 Mar 16;10(3):e0120194
pubmed: 25775479
Acta Neuropathol Commun. 2018 Oct 19;6(1):108
pubmed: 30340518
J Immunol. 2007 May 15;178(10):6557-66
pubmed: 17475886
Intractable Rare Dis Res. 2019 May;8(2):120-128
pubmed: 31218162
AJNR Am J Neuroradiol. 1994 Oct;15(9):1761-6
pubmed: 7847225
Mol Neurobiol. 2020 Jul;57(7):2920-2933
pubmed: 32436108
Brain. 2017 Apr 1;140(4):953-966
pubmed: 28375456
Hum Mutat. 2001 Dec;18(6):499-515
pubmed: 11748843
J Child Neurol. 2009 Sep;24(9):1147-57
pubmed: 19605772
J Clin Invest. 1994 Mar;93(3):1288-92
pubmed: 8132768
Lancet Neurol. 2007 Aug;6(8):687-92
pubmed: 17618834
Clin Biochem. 2003 Oct;36(7):553-6
pubmed: 14563449
Neurobiol Dis. 2018 Dec;120:1-11
pubmed: 30149180
Biol Blood Marrow Transplant. 2020 Oct;26(10):1894-1899
pubmed: 32599216
N Engl J Med. 2017 Oct 26;377(17):1630-1638
pubmed: 28976817
FEBS Open Bio. 2016 Jul 30;6(9):902-13
pubmed: 27642553